ASTRO/ASCO/AUA Guideline on Hypofractionation for Localized Prostate Cancer
Published: Web posted: October 2026
This guideline applies to patients with localized (N0M0) prostate cancer receiving EBRT as primary local therapy. This includes patients with low-risk prostate cancer who have declined active surveillance and those patients with intermediate-, high-, and very high-risk localized prostate cancer who have chosen EBRT as their primary local treatment modality. This guideline replaces ASTRO's original 2018 guideline on the same topic.
Developed in collaboration with:
- American Society of Clinical Oncology
- American Urological Association
- European Society for Radiotherapy and Oncology
- Society of Urologic Oncology
Endorsed by:
- American Urological Association
- European Society for Radiotherapy and Oncology
- The Royal Australian and New Zealand College of Radiologists
- Society of Urologic Oncology
Resources:
- Guideline slide set
- Press release
